Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus VESICARE LS.
CANTIL vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic